Vacunas最新文献_第10页

Effects of sub-inhibitory concentration of antibiotic and heat stress on the expression of type II TA system genes in Brucella spp. 抗生素亚抑制浓度和热应激对布鲁氏菌ⅱ型TA系统基因表达的影响。

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.03.002

Fatemeh Amraei , Negar Narimisa , Shiva Mirkalantari , Shabnam Razavi , Behrooz Sadeghi Kalani , Faramarz Masjedian Jazi

{"title":"Effects of sub-inhibitory concentration of antibiotic and heat stress on the expression of type II TA system genes in Brucella spp.","authors":"Fatemeh Amraei , Negar Narimisa , Shiva Mirkalantari , Shabnam Razavi , Behrooz Sadeghi Kalani , Faramarz Masjedian Jazi","doi":"10.1016/j.vacun.2023.03.002","DOIUrl":"10.1016/j.vacun.2023.03.002","url":null,"abstract":"<div><h3>Objective</h3><p>Bacteria can react to stress conditions using the Toxin-Antitoxin (TA) system. This study investigated the expression of TA system genes under heat and antibiotic stresses in <span><em>Brucella</em></span> spp.</p></div><div><h3>Methods</h3><p><span><span>To determine the effects of sub-inhibitory concentration (sub-MIC) of rifampin on </span>bacterial survival<span> and growth, a colony-forming unit was quantitated, and turbidity was assessed following the treatment of </span></span><em>Brucella</em><span> isolates, with ½ minimum inhibitory concentration (MIC) of antibiotic at different time intervals. Also, </span><em>Brucella</em> isolates were exposed to heat stress (42 °C) compared to the control (37 °C). Finally, the expression of TA system genes in <em>Brucella</em><span> isolates was evaluated one hour after treatment using the quantitative reverse transcription PCR (qRT-PCR) method.</span></p></div><div><h3>Results</h3><p>Our results showed that the growth of the <em>Brucella</em> isolates reduced in the presence of the sub-MIC of antibiotics compared to the control. The results of the qPCR assay showed that, in the presence of rifampicin the expression of the TA system genes increased and, under the heat stress conditions, the expression of the TA system genes increased compared to controls expect brnT / brnA system.</p></div><div><h3>Conclusion</h3><p>Although the exact role of the TA system in response to various stresses is not yet fully understood, our study provided information on the effectiveness of the type II TA system under heat and antibiotic stress conditions by examining the gene expression of type II systems in <em>Brucella</em> isolates.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"24 4","pages":"Pages 266-272"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41257257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The feasibility of including human papillomavirus vaccine in Iran's national immunization program 将人乳头瘤病毒疫苗纳入伊朗国家免疫规划的可行性

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.06.002

Maryam Honarvar , Reza Goudarzi , Mohammadreza Amiresmaili , Asrin Amiri , Abdul Sami Saeed Paul

{"title":"The feasibility of including human papillomavirus vaccine in Iran's national immunization program","authors":"Maryam Honarvar , Reza Goudarzi , Mohammadreza Amiresmaili , Asrin Amiri , Abdul Sami Saeed Paul","doi":"10.1016/j.vacun.2023.06.002","DOIUrl":"10.1016/j.vacun.2023.06.002","url":null,"abstract":"<div><h3>Aim</h3><p>Cervical cancer is the second most common form of cancer in women. In order to prevent this disease, several vaccines like Cervarix<span> [2vHPV], Cecolin, Cervarix quadrivalent and Gardasil [9vHPV]), have been included in the vaccination program of some countries. This study as a part of Health Technology Assessment (HTA), aimed to assess the feasibility of inclusion of Human Papilloma Virus (HPV) vaccine in the national vaccination program of Iran.</span></p></div><div><h3>Subject and methods</h3><p>This is a qualitative case study composed of semi structured interviews with a purposive sample of experts working extensively in the field of women's health. Data saturation reached at the 12th interview. The data was analyzed using the framework method.</p></div><div><h3>Results</h3><p>A total of 14 subthemes under 6 themes of the need for vaccines, lack of knowledge, cost factors, administration at early ages, creating a negative mindset, and empowering the society were identified.</p></div><div><h3>Conclusion</h3><p>Including HPV vaccine in the national vaccination program not only seems justifiable, but also its absence in the vaccination program violates some aspects of medical ethics<span> principles. Therefore, the government must take steps to increase public awareness about human papillomavirus and include the aforementioned vaccine in the national vaccination program.</span></p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"24 4","pages":"Pages 298-307"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42068625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The global spread of human monkeypox virus: Challenges and opportunities for prevention 人类猴痘病毒的全球传播:预防的挑战和机遇

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.07.002

Muhammad Safdar , Shafeeq Ur Rehman , Furqan Shafqat , Muhammad Shan , Samiha S. Khan , Faiz-ul Hassan , Hafiz Khawar Ali , Mehmet Ozaslan

{"title":"The global spread of human monkeypox virus: Challenges and opportunities for prevention","authors":"Muhammad Safdar , Shafeeq Ur Rehman , Furqan Shafqat , Muhammad Shan , Samiha S. Khan , Faiz-ul Hassan , Hafiz Khawar Ali , Mehmet Ozaslan","doi":"10.1016/j.vacun.2023.07.002","DOIUrl":"https://doi.org/10.1016/j.vacun.2023.07.002","url":null,"abstract":"<div><p><span>This review comprehensively analyses human monkeypox<span><span> caused by the monkeypox virus (MPXV), including its origins, transmission, pathogenesis, immune responses, genetic variations, evolutionary changes, and potential therapeutic strategies. The MPXV belongs to the </span>Poxviridae family and is responsible for the </span></span>zoonotic<span><span> viral disease known as human monkeypox (MPX). A multi-nation monkeypox epidemic was declared by the WHO in May 2022, with over 64 290 laboratory-confirmed cases recorded worldwide in several non-endemic countries. Symptoms of MPX include fever, headache, muscular aches, </span>lymphadenopathy<span><span>, and a recognizable rash that progresses into papules, vesicles, and pustules before finally scabbing over and healing. MPXV is endemic to sub-Saharan Africa, affecting wild animals and resulting in zoonotic epidemics. Delayed vaccination, commerce in exotic animals, international travel, and increased human sensitivity have contributed to the spread of MPXV to new locations. The </span>smallpox vaccination may provide cross-protection against MPXV due to antigenic similarities. Basic health precautions should be followed, including frequent handwashing, nose and mouth covering when coughing, and avoiding ill individuals and overcrowded areas. Safe sexual practices are also recommended in countries reporting monkeypox transmission. Although vaccines are available, but they are limited. The review highlights the need for effective preventive and therapeutic strategies to manage human monkeypox.</span></span></p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"24 4","pages":"Pages 364-379"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92013974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiological study of vaccination against SARS-CoV-2 and its impact on COVID-19 progression in a cohort of patients in gran Canaria 大加那利岛一组患者接种SARS-CoV-2疫苗的流行病学研究及其对COVID-19进展的影响

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.06.005

Alejandro de Arriba Fernández , José Luis Alonso Bilbao , Alberto Espiñeira Francés , Antonio Cabeza Mora , Ángela Gutiérrez Pérez , Miguel Ángel Díaz Barreiros

{"title":"Epidemiological study of vaccination against SARS-CoV-2 and its impact on COVID-19 progression in a cohort of patients in gran Canaria","authors":"Alejandro de Arriba Fernández , José Luis Alonso Bilbao , Alberto Espiñeira Francés , Antonio Cabeza Mora , Ángela Gutiérrez Pérez , Miguel Ángel Díaz Barreiros","doi":"10.1016/j.vacun.2023.06.005","DOIUrl":"10.1016/j.vacun.2023.06.005","url":null,"abstract":"<div><h3>Objectives</h3><p>We analyzed the impact of age, sex, vaccination against COVID-19, immunosuppressive treatment, and comorbidities on patients' risk of requiring hospital admission or of death.</p></div><div><h3>Methods</h3><p>Population-based observational retrospective study conducted on a cohort of 19,850 patients aged 12 years or more, who were diagnosed with COVID-19 between June 1st and December 31st, 2021, in the island of Gran Canaria.</p></div><div><h3>Results</h3><p>Hypertension (18.5%), asthma (12.8%) and diabetes (7.2%) were the most frequent comorbidities; 147 patients died (0.7%). The combination of advanced age, male sex, cancer, coronary heart disease, immunosuppressive treatment, hospital admission, admission to the intensive care unit, mechanical ventilation and lack of complete COVID-19 vaccination or booster dose was strongly predictive of mortality (p < 0.05); 831 patients required hospital admission and it was more frequent in men, older age groups, and patients with cancer, diabetes, arterial hypertension, chronic obstructive pulmonary disease, congestive heart failure or immunosuppressive treatment. The COVID-19 vaccine booster dose was associated with a lower risk of death ([OR] 0.11, 95% CI 0.06–0.21, p < 0.05) or hospital admission ([OR] 0.36, 95% CI 0.29–0.46, p < 0.05).</p></div><div><h3>Conclusions</h3><p>Cancer, coronary heart disease, and immunosuppressive treatment were associated with increased COVID-19 mortality. More complete vaccination was associated with lower risk of hospital admission or death. Three doses of the SARS-CoV-2 vaccine were highly associated with the prevention of death and hospital admission in all age groups. These findings suggest that COVID-19 vaccination can help bring the pandemic under control.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"24 4","pages":"Pages 308-316"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9709755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1), the next medical revolution against cancer CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1)，抗癌的下一个医学革命

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.01.006

Ali Adel Dawood

{"title":"CHECKvacc (HOV3, CF33-hNIS-anti-PD-L1), the next medical revolution against cancer","authors":"Ali Adel Dawood","doi":"10.1016/j.vacun.2023.01.006","DOIUrl":"10.1016/j.vacun.2023.01.006","url":null,"abstract":"<div><p><span><span><span>Despite advances in modern treatment, many cancers have evolved to bypass the immune system. The immune system either cannot perceive the tumor as foreign or the immune response is hindered. </span>Oncolytic viruses<span> are designed to infect and kill cancer cells<span>. A huge variety of oncolytic viruses<span><span> have been produced and tested over the last 30 years. The presence of 9 different virus strains in the cells (mouse) at the same time allowed the genes from the different strains to be rearranged via homologous recombination to generate unique chimeric daughter viruses. CHECKvacc is a genetically engineered oncolytic virus (CF33) that is equipped with the human </span>sodium iodide symporter<span> (hNIS) and an anti-PD-L1 antibody. The novel modified viruses will be examined as a monotherapy or in combination with </span></span></span></span></span>pembrolizumab to determine the safety and efficacy of the treatment regimens. The first patient was dosed in a phase 1 </span>clinical trial<span> to assess the treatment's safety in people with advanced solid tumors. The medicine will be administered either directly into the tumors or intravenously.</span></p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"24 4","pages":"Pages 358-363"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55179959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 immune response in adults post Measles-Rubella vaccination 成人麻疹-风疹疫苗接种后的COVID-19免疫反应

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.05.004

Suwoyo Suwoyo, Erna Rahma Yani, Koekoeh Hardjito

{"title":"COVID-19 immune response in adults post Measles-Rubella vaccination","authors":"Suwoyo Suwoyo, Erna Rahma Yani, Koekoeh Hardjito","doi":"10.1016/j.vacun.2023.05.004","DOIUrl":"https://doi.org/10.1016/j.vacun.2023.05.004","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to see how measles, mumps, and rubella vaccination affected the increase in SARS-CoV-2 immunoglobulin levels in individuals who had received the second dose of the SARS-CoV-2 vaccine.</p></div><div><h3>Material and method</h3><p>This research is a quasi-experimental type with a pre-post test design. The population studied were adults who had received the second dose of the SARS-CoV-2 vaccine, consisting of 30 people.</p></div><div><h3>Results</h3><p>The results of this study were that most (60%) research subjects experienced an increase in IgM and some subjects (46.6%) experienced an increase in anti-SARS-CoV-2 IgG levels. The administration of the MR vaccination had no effect on increasing anti-SARS-CoV-2 IgG and IgM levels. This happened because the increase in IgM and IgG levels in the pre and post-tests in most research subjects was relatively low.</p></div><div><h3>Conclusion</h3><p>The administration of the MR vaccine to adults who had received a second dose of the SARS-CoV-2 vaccine elicited a response with low levels of IgG and IgM SARS-CoV-2.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"24 4","pages":"Pages 341-347"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1576988723000365/pdfft?md5=b76809598cf6e41e652ab0d7bc117b12&pid=1-s2.0-S1576988723000365-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92146298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Fe de erratas de artículos publicados en la revista Vacunas 发表在《疫苗》杂志上的文章的勘误表

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.09.003

引用次数: 0

The impact of vaccination against monkeypox on risk of mpox reinfection 猴痘疫苗接种对麻疹再感染风险的影响

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.06.003

Farhad Dadgar , Jalil Rouhani , Fatemeh Dehghani , Masoud Keikha

引用次数: 0

Vacunación frente al SARS-CoV-2 en otoño de 2023: ¿a quién y cómo hay que vacunar? 2023年秋季SARS-CoV-2疫苗接种:给谁接种，如何接种?

Vacunas Pub Date : 2023-10-01 DOI: 10.1016/j.vacun.2023.08.001

Fernando Moraga-Llop , Magda Campins-Martí

引用次数: 0